Developing Global Research Capacity
Aeras’ global partners include academic, public and private institutions, which work together to build research capacity, install diagnostic and immunology lab infrastructure, and provide training and employment to world-class researchers.
South Africa is particularly poised as a key driver of TB vaccine innovation, since it has the highest incidence of the disease and is well-equipped with world-renowned researchers and infrastructure to conduct TB studies. Our in-country partners provide primary and follow-up care to communities involved in clinical trials. They educate the local communities and raise awareness about TB and vaccine trials.
Recently, the successful completion of the first large, Phase IIb trial in South Africa of nearly 3,000 infants showed that it is possible to conduct a trial of that scope and magnitude, even though the vaccine did not prove to be more efficacious than the widely used infant vaccine BCG.